Truqap gains US approval in PTEN-deficient metastatic prostate cancer
Decision brief
Answer first · skim in under a minute
AstraZeneca’s Truqap (capivasertib) has been approved in the US with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer. The move creates a first-in-class targeted option and a new catalyst to watch for BD teams, investors, and analysts.
Truqap prostate cancer use expanded on June 12, 2026, when FDA approved capivasertib with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive disease. CAPItello-281 showed median rPFS of 33.2 months versus 25.7 months for placebo plus abiraterone.
Contents9 sections
Key Takeaways
- Truqap prostate cancer approval covers PTEN-deficient mAPMN/S disease with abiraterone and prednisone.
- CAPItello-281 enrolled 1,012 adults; rPFS HR was 0.81 (33.2 vs 25.7 months).
- VENTANA PTEN (SP218) RxDx is the companion diagnostic for patient selection.
- Overall survival remained immature at the rPFS analysis; hyperglycemia and other labeled risks apply.
What did FDA approve for Truqap prostate cancer?
FDA approved Truqap in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is PTEN-deficient on an FDA-authorized test. The disease category was previously often called metastatic hormone-sensitive prostate cancer. Full agency language is on the FDA capivasertib approval page.
What did CAPItello-281 show?
Efficacy was evaluated in CAPItello-281 (NCT04305496), a randomized, double-blind, placebo-controlled trial in 1,012 adults with newly diagnosed PTEN-deficient mAPMN/S prostate cancer. PTEN deficiency used central immunohistochemistry with the VENTANA PTEN (SP218) assay.
- Median rPFS: 33.2 months (95% CI 25.8–44.2) with capivasertib plus abiraterone
- Median rPFS: 25.7 months (95% CI 22.0–29.9) with placebo plus abiraterone
- Hazard ratio 0.81 (95% CI 0.66–0.98); two-sided p=0.034
- Overall survival immature at the rPFS analysis
Prescribing details, including the 400 mg twice-daily 4-days-on/3-days-off schedule, appear in DailyMed Truqap labeling.
Why PTEN selection matters
PTEN loss activates PI3K/AKT signaling and is common in aggressive prostate cancers. Biomarker selection is mandatory for this indication, not optional enrichment. Teams should plan assay logistics alongside androgen pathway therapy and abiraterone supply.
What should oncology and access teams watch next?
Watch companion-diagnostic adoption rates, hyperglycemia management burden, payer criteria tied to PTEN IHC, and mature overall survival. Related NovaPharma notes cover U.S. and EU framing of the same FDA decision and broader prostate oncology catalysts.
Trial registration context is on ClinicalTrials.gov NCT04305496.
What remains unproven
Overall survival superiority is not yet demonstrated. Benefits outside PTEN-deficient mAPMN/S disease should not be assumed. Cross-trial comparisons with other intensified mHSPC regimens remain hypothesis-generating only.
Related NovaPharma coverage
- FDA Approves Capivasertib for PTEN-Deficient Prostate Cancer
- FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC
- Pfizer sharpens prostate cancer case with Talzenna win
Frequently Asked Questions
What is the new Truqap prostate cancer indication?
On June 12, 2026, FDA approved Truqap (capivasertib) with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer that is PTEN-deficient as detected by an FDA-authorized test.
What trial supported Truqap prostate cancer approval?
CAPItello-281 (NCT04305496) enrolled 1,012 adults with newly diagnosed PTEN-deficient mAPMN/S prostate cancer. Median radiographic progression-free survival was 33.2 months with capivasertib plus abiraterone versus 25.7 months with placebo plus abiraterone (HR 0.81; 95% CI 0.66–0.98; p=0.034). Overall survival data were immature.
Is a companion diagnostic required for Truqap prostate cancer use?
Yes. FDA also approved the VENTANA PTEN (SP218) RxDx Assay as a companion diagnostic to identify PTEN-deficient prostate cancer for capivasertib treatment. Recommended Truqap dosing is 400 mg orally twice daily for 4 days followed by 3 days off.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Truqap.
Unlock full calendar →AstraZeneca AB pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
